Publicaciones (24) Publicaciones de Jesús Martínez Cadilla

2024

  1. Long-term benefit of ustekinumab in ulcerative colitis in clinical practice: ULISES study

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 10, pp. 1325-1338

2023

  1. Real world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness, safety and impact of extraintestinal manifestations and immunomediated diseases

    Meeting Abstract

  2. Real-World Evidence of Tofacinitib in Ulcerative Colitis: Short-Term and Long-Term Effectiveness and Safety

    American Journal of Gastroenterology, Vol. 118, Núm. 7, pp. 1237-1247

2022

  1. Incidence of inflammatory bowel disease and phenotype at diagnosis in 2011: results of the Epi-IBD 2011 study in the Vigo area

    Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva, Vol. 114, Núm. 2, pp. 103-106

  2. Long-Term Real-World Effectiveness and Safety of Ustekinumab in Crohn's Disease Patients: The SUSTAIN Study

    Inflammatory bowel diseases, Vol. 28, Núm. 11, pp. 1725-1736

  3. Using Interpretable Machine Learning to Identify Baseline Predictive Factors of Remission and Drug Durability in Crohn’s Disease Patients on Ustekinumab

    Journal of Clinical Medicine, Vol. 11, Núm. 15

2021

  1. Effectiveness of ustekinumab in fistulising perianal Crohn′s disease refractory or intolerant to anti-TNF

    Journal of Crohn's and Colitis, Vol. 15, Núm. Supplement_1, pp. S419-S420

  2. Impact of biological agents on postsurgical complications in inflammatory bowel disease: A multicentre study of geteccu

    Journal of Clinical Medicine, Vol. 10, Núm. 19

  3. Tofacitinib in ulcerative colitis: Real-world evidence from the ENEIDA registry

    Journal of Crohn's and Colitis, Vol. 15, Núm. 1, pp. 35-42

  4. Treatment of abdominal fistulas in Crohn’s disease and monitoring with abdominal ultrasonography

    Revista Española de Enfermedades Digestivas, Vol. 113, Núm. 4, pp. 240-245

2020

  1. Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study

    The Lancet Gastroenterology and Hepatology, Vol. 5, Núm. 5, pp. 454-464

2019

  1. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

    Therapeutic Advances in Gastroenterology, Vol. 12

  2. Increased risk of thiopurine-related adverse events in elderly patients with IBD

    Alimentary Pharmacology and Therapeutics, Vol. 50, Núm. 7, pp. 780-788

2017

  1. Nuevas moléculas, un abordaje de práctica clínica: Vedolizumab

    Inflamatoria: Revista oficial del grupo EIGA, Núm. 11, pp. 2-7

  2. Occurrence of anaemia in the first year of inflammatory bowel disease in a European population-based inception cohort-An ECCO-EpiCom study

    Journal of Crohn's and Colitis, Vol. 11, Núm. 10, pp. 1213-1222

  3. Sweet's Syndrome: An Unusual Extraintestinal Manifestation of Inflammatory Bowel Disease

    American Journal of Gastroenterology

  4. Valoración de la adhesión terapéutica en la enfermedad inflamatoria intestinal. Comparación entre una escala de autoevaluación y un índice farmacéutico de dispensación de medicamentos

    Revista Espanola de Enfermedades Digestivas, Vol. 109, Núm. 8, pp. 542-551

2016

  1. Tuberculosis in anti-tumour necrosis factortreated inflammatory bowel disease patients after the implementation of preventive measures: Compliance with recommendations and safety of retreatment

    Journal of Crohn's and Colitis, Vol. 10, Núm. 10

2015

  1. Incidence and phenotype at diagnosis of inflammatory bowel disease. Results in Spain of the EpiCom study

    Gastroenterologia y Hepatologia, Vol. 38, Núm. 9, pp. 534-540

2011

  1. La tuberculosis en pacientes candidatos o en tratamiento con fármacos biológicos

    Inflamatoria: Revista oficial del grupo EIGA, Núm. 6, pp. 7-15